サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：性器ヘルペス治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1176520

性器ヘルペス治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）

Genital Herpes Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
性器ヘルペス治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月01日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の性器ヘルペス治療薬の市場規模は、2022年から2030年の予測期間中に4.9％のCAGRで成長すると予想されています。性器ヘルペスの有病率の上昇、早期診断と性器ヘルペス治療のための医療介入をもたらす診断センターの発展、性感染症に対する公衆衛生意識の高まり、性器ヘルペス感染の拡大を抑制するための政府の積極的な政策は、市場の成長を促進しています。

当レポートでは、世界の性器ヘルペス治療薬市場について調査分析し、競合分析、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の性器ヘルペス治療薬市場
  • 世界の性器ヘルペス治療薬市場（100万米ドル）（2021年）：薬剤クラス別
  • 世界の性器ヘルペス治療薬市場（100万米ドル）：地域別
  • 魅力的な投資提案（2021年）：地域別

第3章 性器ヘルペス治療薬市場：競合分析

  • 主要な性器ヘルペス治療薬市場ベンダーの市場ポジショニング
  • 性器ヘルペス治療薬市場ベンダーが採用する戦略
  • 主要な業界戦略
  • 階層分析：2021年と2030年の比較

第4章 性器ヘルペス治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の性器ヘルペス治療薬の市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）：薬剤クラス別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • アシクロビル
    • ファムシクロビル
    • バラシクロビル
    • パイプライン分析

第6章 北米の性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）

第7章 英国および欧州連合の性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）

第8章 アジア太平洋の性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）

第9章 ラテンアメリカの性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）

第10章 中東およびアフリカの性器ヘルペス治療薬市場、米ドル（100万）（2020年～2030年）

第11章 企業プロファイル

  • AstraZeneca, Plc.
  • Apotheca, Inc.
  • Asahi Kasei Pharma Corporation
  • Carlsbad Technology, Inc.
  • GlaxoSmithKline plc.
  • Mylan N.V.
  • Novartis AG
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals, Inc.
図表

List of Tables

  • TABLE 1 Global Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 2 Global Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 3 Global Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 4 North America Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 5 North America Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 6 North America Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 7 U.S. Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 8 U.S. Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 9 U.S. Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 10 Canada Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 11 Canada Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 12 Canada Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 19 UK Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 20 UK Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 21 UK Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 22 Germany Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 23 Germany Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 24 Germany Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 25 Spain Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 26 Spain Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 27 Spain Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 28 Italy Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 29 Italy Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 30 Italy Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 31 France Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 32 France Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 33 France Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 37 Asia Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 38 Asia Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 39 Asia Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 40 China Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 41 China Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 42 China Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 43 Japan Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 44 Japan Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 45 Japan Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 46 India Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 47 India Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 48 India Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 49 Australia Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 50 Australia Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 51 Australia Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 52 South Korea Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 53 South Korea Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 54 South Korea Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 55 Latin America Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 56 Latin America Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 57 Latin America Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 58 Brazil Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 59 Brazil Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 60 Brazil Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 61 Mexico Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 62 Mexico Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 63 Mexico Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 70 GCC Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 71 GCC Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 72 GCC Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 73 Africa Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 74 Africa Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 75 Africa Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Genital Herpes Treatment Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Genital Herpes Treatment Drugs Market By Pipeline Analysis , 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Genital Herpes Treatment Drugs Market By Phase III Drugs , 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Genital Herpes Treatment Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Genital Herpes Treatment Drugs Market: Quality Assurance
  • FIG. 5 Global Genital Herpes Treatment Drugs Market, By Drug Class , 2021
  • FIG. 6 Global Genital Herpes Treatment Drugs Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Genital Herpes Treatment Drugs Market, 2021
  • FIG. 8 Market Positioning of Key Genital Herpes Treatment Drugs Market Players, 2021
  • FIG. 9 Global Genital Herpes Treatment Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Genital Herpes Treatment Drugs Market, By Drug Class , 2021 Vs 2030, %
  • FIG. 11 U.S. Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 France Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 China Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 India Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Genital Herpes Treatment Drugs Market (US$ Million), 2020 - 2030
目次
Product Code: 138527-08-22

Industry Outlook

The genital herpes treatment drugs market will be featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2022 to 2030. According to the latest research citing's published by World Health Organization (WHO), approximately two-thirds of the global population under 50 years of age is infected with herpes simplex virus type 1 (HSV-1). Genital herpes is contagious and transmitted via the vaginal and anal route. It is important for any individual to visit health clinic when symptoms such as small blisters around thigh, genital, or anal region are visible. Burning sensation and pain during micturition is also an early symptom related to genital herpes infection.

The product pipeline is strong with drugs such as GEN-003 a therapeutic vaccine developed by Genocea Biosciences, Inc. is currently under phase 3 clinical trial studies with promising result in reduction of genital lesions. Vical, Inc. is developing VCL-HB01 a therapeutic vaccine which is showcasing excellent results in the treatment of lesion recurrence.

Excellent pharmacodynamic and pharmacokinetic profile makes acyclovir the first line therapeutic drug for the treatment for genital herpes

Acyclovir is currently dominating the drug class segment for genital herpes treatment drugs market. The key attributes contributing towards the dominance of acyclovir are excellent pharmacodynamic and pharmacokinetic parameters. Clinical studies have fortified the facts that acyclovir is safe, well tolerated in patients suffering with genital herpes infection. It is the first line drug therapy due to its ability to inhibit and inactivate HSV specific DNA polymerase to prevent viral DNA synthesis without causing any harm to normal cellular process. The recommended dose is 200 mg five times daily for 10 days. Famciclovir will be the fastest growing antiviral drug during the forecast period 2018 to 2026. Improved bioavailability of famciclovir is useful in the suppression of recurrent genital herpes infection in immunocompromised patients.

Rising prevalence of genital herpes drive the market growth in North America

North America is leading the regional segment for genital herpes treatment drugs market. According to Center for Disease Control and Prevention (CDC) statistics genital herpes is prevalent in every sixth person aged between 14 to 49 years. The major factors influencing the market growth in North America are rising prevalence of genital herpes and developed diagnostic centers resulting in early diagnosis and medical intervention for treating genital herpes. In Europe the market is driven by factors such as existence of key players such as GlaxoSmithkline, Plc., Novartis AG, AstraZeneca, Plc., etc. and recent refugee influx from the Levant region has resulted in a steep increase in the genital herpes infection. Asia Pacific is set to become the fastest growing regional market during the forecast period on account of rising public health awareness regarding sexually transmitted disease, proactive government policies in curbing the spread of genital herpes infection and presence of huge generic drugs market employed for treatment.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Genital Herpes Treatment Drugs market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Genital Herpes Treatment Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Acyclovir
  • Famciclovir
  • Valacyclovir
  • Pipeline Analysis
    • Phase III Drugs
      • GEN-003
      • VCL-HB01
    • Tabular Representation of Drug Pipeline in Phase II and I

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Genital Herpes Treatment Drugs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Genital Herpes Treatment Drugs market?
  • Which is the largest regional market for Genital Herpes Treatment Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Genital Herpes Treatment Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Genital Herpes Treatment Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Genital Herpes Treatment Drugs Market
  • 2.2. Global Genital Herpes Treatment Drugs Market, By Drug Class , 2021 (US$ Million)
  • 2.3. Global Genital Herpes Treatment Drugs Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Genital Herpes Treatment Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Genital Herpes Treatment Drugs Market Vendors
  • 3.2. Strategies Adopted by Genital Herpes Treatment Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Genital Herpes Treatment Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Genital Herpes Treatment Drugs Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Acyclovir
    • 5.3.2. Famciclovir
    • 5.3.3. Valacyclovir
    • 5.3.4. Pipeline Analysis
      • 5.3.4.1. Phase III Drugs
        • 5.3.4.1.1. GEN-003
        • 5.3.4.1.2. VCL-HB01
      • 5.3.4.2. Tabular Representation of Drug Pipeline in Phase II and I

6. North America Genital Herpes Treatment Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 6.3.Genital Herpes Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

7. UK and European Union Genital Herpes Treatment Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 7.3.Genital Herpes Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

8. Asia Pacific Genital Herpes Treatment Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 8.3.Genital Herpes Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

9. Latin America Genital Herpes Treatment Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 9.3.Genital Herpes Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

10. Middle East and Africa Genital Herpes Treatment Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 10.3.Genital Herpes Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Genital Herpes Treatment Drugs Market: By Drug Class , 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AstraZeneca, Plc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Apotheca, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Asahi Kasei Pharma Corporation
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Carlsbad Technology, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. GlaxoSmithKline plc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Mylan N.V.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Novartis AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Merck & Co., Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Teva Pharmaceutical Industries Ltd.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Zydus Pharmaceuticals, Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives